Cobimetinib (GDC-0973, RG7420) is a potent, selective, and orally available MEK1 inhibitor (IC50 = 4.2 nM) with high kinase selectivity. It induces differentiation and apoptosis in cancer cells and enhances efficacy in combination therapies. Reagent grade, for research purpose.
Usually ships within 24 hours.